One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
Rates of and Factors Associated With Patient Withdrawal of Consent in Cancer Clinical Trials
Shauna L. Hillman, MS1; Aminah Jatoi, MD2,3; Carrie A. Strand, BS1; Jane Perlmutter, PhD4; Suzanne George, MD5; Sumithra J. Mandrekar, PhD1
doi : 10.1001/jamaoncol.2023.1648
August 2023, Vol 9, No. 8, Pages 1026-1155
Integrating On-Treatment Modified Glasgow Prognostic Score and Imaging to Predict Response and Outcomes in Metastatic Renal Cell Carcinoma
Jonas Saal, MD1,2,3; Tobias Bald, PhD2,3; Markus Eckstein, MD4,5; Damian J. Ralser, MD2,3,6; Manuel Ritter, MD3,7; Peter Brossart, MD1,3; Viktor Grünwald, MD8,9; Michael Hölzel, MD2,3; Jörg Ellinger, MD3,7; Niklas Klümper, MD2,3,7
Weekly Adaptive Radiotherapy vs Standard Intensity-Modulated Radiotherapy for Improving Salivary Function in Patients With Head and Neck Cancer
Joël Castelli, MD, PhD1; Juliette Thariat, MD, PhD2; Karen Benezery, MD3; Ali Hasbini, MD4; Bernard Gery, MD2; Antoine Berger, MD5; Xavier Liem, MD6; Sébastien Guihard, MD7; Sophie Chapet, MD8; Sébastien Thureau, MD, PhD9; Pierre Auberdiac, MD10; Pascal Pommier, MD, PhD11; Amandine Ruffier, MD8; Lionel Perrier, PhD12; Anne Devillers, MD13; Boris Campillo-Gimenez, MD1; Renaud de Crevoisier, MD, PhD1
Risk Factors for Progression and Toxic Effects After Preoperative Stereotactic Radiosurgery for Patients With Resected Brain Metastases
Roshan S. Prabhu, MD, MS1,2; Tobi Akinyelu, BS1; Zachary K. Vaslow, MD3; Jennifer K. Matsui, PhD4; Neda Haghighi, MD5,6; Tu Dan, MD7; Mark V. Mishra, MD8; Erin S. Murphy, MD9; Susan Boyles, RTT3; Haley K. Perlow, MD4; Joshua D. Palmer, MD4; Cristian Udovicich, MBBS, MD5; Toral R. Patel, MD7; Zabi Wardak, MD7; Graeme F. Woodworth, MD8; Alexander Ksendzovsky, MD, PhD8; Kailin Yang, MD, PhD9; Samuel T. Chao, MD9; Anthony L. Asher, MD1,10; Stuart H. Burri, MD1,2
Association Between Duration of Immunotherapy and Overall Survival in Advanced Non–Small Cell Lung Cancer
Lova Sun, MD, MSCE1; Benjamin Bleiberg, MD1; Wei-Ting Hwang, PhD2; Melina E. Marmarelis, MD, MSCE1; Corey J. Langer, MD1; Aditi Singh, MD1; Roger B. Cohen, MD1; Ronac Mamtani, MD, MSCE1; Charu Aggarwal, MD, MPH1
Radiotherapy Use and Incidence of Locoregional Recurrence in Patients With Favorable-Risk, Node-Positive Breast Cancer Enrolled in the SWOG S1007 Trial
Reshma Jagsi, MD, DPhil1; William E. Barlow, PhD2; Wendy A. Woodward, MD, PhD3; Eileen Connolly, MD, PhD4; Reshma Mahtani, DO5; Dean Shumway, MD6; Corey Speers, MD, PhD7; Shane R. Stecklein, MD, PhD8; Youssef Zeidan, MD, PhD9; Hong Zhang, MD, PhD10; Priyanka Sharma, MD8; Lajos Pusztai, MD, DPhil11; Gabriel N. Hortobagyi, MD3; Kevin Kalinsky, MD, MS1
US Cancer Mortality Trends Among Hispanic Populations From 1999 to 2020
Isabella R. Pompa, BA1; Anushka Ghosh, BS1; Shamik Bhat, BS2; Siri Ragala3; Anita Nwiloh, BS4; Nabeel Rasheed3; Fumiko Chino, MD5; Henning Willers, MD1; Saveli Goldberg, PhD1; Sophia C. Kamran, MD1
Camrelizumab Plus Apatinib and Temozolomide as First-Line Treatment in Patients With Advanced Acral Melanoma
Lili Mao, MD1; Bin Lian, MD1; Caili Li, MD1; Xue Bai, MD1; Li Zhou, MD2; Chuanliang Cui, MD2; Zhihong Chi, MD1; Xinan Sheng, MD2; Xuan Wang, MD1; Bixia Tang, MD1; Xieqiao Yan, MD2; Siming Li, MD2; Yan Kong, PhD1; Jie Dai, PhD1; Xiaoting Wei, MD1; Juan Li, MD2; Rong Duan, MD2; Huayan Xu, MD2; Xiaowen Wu, MD2; Yue Yang, MD1; Fengzhuo Cheng, MPH3; Cheng Zhang, MD3; Fangzhou Xia, MD3; Zheng Pang, MM3; Jun Guo, MD, PhD1; Lu Si, MD1
Clinical Features and Risk Factors Associated With Multisystem Inflammatory Syndrome in Children With Cancer and COVID-19
Samantha D. Martin, MD1; Elizabeth S. Davis, MPH2; Chen Dai, MS2; Lauren H. Boal, MD1; Brook Araya, BA2; Julienne Brackett, MD3; David Dickens, MD4; Alissa Kahn, MD5; Isaac Martinez, BA2; Archana Sharma, MD6; Carla Schwalm, MD7; Paibel Aguayo-Hiraldo, MD8; Smita Bhatia, MD, MPH2,9; Jennifer M. Levine, MSW, MD10; Emily E. Johnston, MD, MS2,9; Julie A. Wolfson, MD, MSHS2,9; for the Pediatric Oncology COVID-19 Case Consortium
Assessment of Gender-Specific COVID-19 Case Fatality Risk per Malignant Neoplasm Type
Koji Matsuo, MD, PhD1,2; Rachel S. Mandelbaum, MD1,3; Andrew Vallejo, MD, MS1; Maximilian Klar, MD, MPH4; Lynda D. Roman, MD1,2; Jason D. Wright, MD5
Comparing Risk for Second Primary Cancers After Intensity-Modulated vs 3-Dimensional Conformal Radiation Therapy for Prostate Cancer, 2002-2015
Kishan J. Pithadia, BS1; Pragati G. Advani, MD, DrPH1; Deborah E. Citrin, MD2; Justin E. Bekelman, MD3; Diana R. Withrow, PhD1; Amy Berrington de Gonzalez, DPhil1; Lindsay M. Morton, PhD1; Sara J. Schonfeld, PhD1
Changes to Primary End Points in Randomized Clinical Trials on Immune Checkpoint Inhibitors in Urothelial, Renal Cell, and Lung Cancers
Anke Richters, PhD1; Hilin Yildirim, MD1; Christopher M. Booth, MD2; Francisco E. Vera Badillo, MD, MS3; Lambertus A. L. M. Kiemeney, PhD4; Katja K. H. Aben, PhD1
An Updated Report on the Prevalence of Prior Cancer Among Persons Newly Diagnosed With Cancer in the Surveillance, Epidemiology, and End Results Program
Caitlin C. Murphy, PhD, MPH1; Guillermo A. Tortolero, MPH1; David E. Gerber, MD2,3,4; Sandi L. Pruitt, PhD, MPH3,4
Adjuvant Treatments for Surgically Resected Non–Small Cell Lung Cancer Harboring EGFR Mutations
Antonio Passaro, MD, PhD1; Tony S. K. Mok, MD2; Ilaria Attili, MD1; Yi-Long Wu, MD3; Masahiro Tsuboi, MD4; Filippo de Marinis, MD1; Solange Peters, MD, PhD5
Diagnosis and Management of Tropomyosin Receptor Kinase Fusion-Positive Thyroid Carcinomas
Robert Haddad, MD1; Rossella Elisei, MD2; Ana O. Hoff, MD3; Zhiyan Liu, MD, PhD4; Fabian Pitoia, MD, PhD5; Giancarlo Pruneri, MD6,7; Peter M. Sadow, MD, PhD8; Fernando Soares, MD, PhD9; Andrew Turk, MD10; Michelle D. Williams, MD11; Lori J. Wirth, MD12,13; Maria E. Cabanillas, MD14
Left Shoulder Fungating Mass in a 46-Year-Old Man
Heng Jiang, MBBS1; Sean C. Figy, MD2; Juan A. Santamaria-Barria, MD3
Approaches to Continuing COVID-19–Related Clinical Research Practices After the Pandemic—Must Cinderella Leave the Ball?
David E. Gerber, MD1,2; Elizabeth K. S. Barksdale, PhD3
Leveraging Goals of Care Interventions to Deliver Personalized Care Near the End of Life
Christopher R. Manz, MD, MSHP1; Gabrielle B. Rocque, MD2,3; Manali I. Patel, MD, MPH4,5
Enhancing Patient Retention in Clinical Trials—Strategies for Success
Dame Idossa, MD1,2; Shruti Patel, MD3; Narjust Florez, MD4,5
Developing an Ideal Risk Stratification Model for Metastatic Renal Cell Carcinoma
Georges Gebrael, MD1; Gliceida Galarza Fortuna, MD1; Neeraj Agarwal, MD1
The Potential of Adaptive Radiotherapy for Patients With Head and Neck Cancer—Too Much or Not Enough?
Beth M. Beadle, MD, PhD1; Annie W. Chan, MD2
The Emerging Paradigm of Preoperative Stereotactic Radiosurgery for Resectable Brain Metastases
Shearwood McClelland III, MD1,2; Debra Nana Yeboa, MD3,4
Clinical Decision-Making in the Real World—The Perfect as the Enemy of the Good
Howard (Jack) West, MD, MPhil1,2
Evidence Base for Health Care Strategies to Protect Vulnerable Patients During the COVID-19 Pandemic
Alyson Haslam, PhD1; Vinay Prasad, MD, MPH1
Evidence Base for Health Care Strategies to Protect Vulnerable Patients During the COVID-19 Pandemic—Reply
Michael Hoerger, PhD, MSCR, MBA1,2,3,4; James Gerhart, PhD5; Maria C. Swartz, PhD, MPH, RD, LD6
Standardized Documentation Is Not the Solution to Reduce Physician Time in the Electronic Health Record
Harry B. Burke, MD, PhD1
Standardized Documentation Is Not the Solution to Reduce Physician Time in the Electronic Health Record—Reply
Peter E. Gabriel, MD1; Aditi P. Singh, MD2; Lawrence N. Shulman, MD1
Assessment and Prognostic Value of Inflammatory Biomarkers in Patients With Colon Cancer
Josh McGovern, MBChB1; Ross D. Dolan, PhD1; Donald C. McMillan, PhD1
Assessment and Prognostic Value of Inflammatory Biomarkers in Patients With Colon Cancer—Reply
En Cheng, MD, PhD1; Jeffrey A. Meyerhardt, MD, MPH2
Net Clinical Benefit as Measure of Treatment Benefit Among Older Adults With Advanced Incurable Non–Small Cell Lung Cancer
Chee Khoon Lee, MBBS (Hons), MMedSci (Clin Epid), MBiostat, PhD1; Elizabeth Driscoll, MBBS (Hons), MPH2
Net Clinical Benefit as Measure of Treatment Benefit Among Older Adults With Advanced Incurable Non–Small Cell Lung Cancer—Reply
Teja Voruganti, MD, PhD1; Carolyn J. Presley, MD, MHS2; Cary P. Gross, MD3
